Raymond James Issues Positive Forecast for Hologic (NASDAQ:HOLX) Stock Price

Hologic (NASDAQ:HOLX) had its price target hoisted by Raymond James from $93.00 to $95.00 in a research report released on Tuesday,Benzinga reports. Raymond James currently has an outperform rating on the medical equipment provider’s stock.

A number of other research firms have also recently weighed in on HOLX. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Evercore ISI lifted their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Down 1.5 %

Shares of HOLX opened at $79.29 on Tuesday. Hologic has a 12 month low of $66.93 and a 12 month high of $84.67. The stock’s 50-day moving average price is $81.02 and its two-hundred day moving average price is $78.13. The company has a market capitalization of $18.42 billion, a PE ratio of 23.81, a PEG ratio of 3.03 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter last year, the firm posted $0.89 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts anticipate that Hologic will post 4.36 EPS for the current year.

Hedge Funds Weigh In On Hologic

A number of institutional investors and hedge funds have recently modified their holdings of HOLX. Wolff Wiese Magana LLC purchased a new stake in Hologic during the 3rd quarter worth about $25,000. Innealta Capital LLC purchased a new stake in Hologic during the second quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. purchased a new position in Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC raised its holdings in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.